Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis

Nanjing University

Status: Completed

Conditions: Secukinumab; Axial Spondylarthritis (axSpA)

Treatments: Drug: Secikinumab

Study type: Observational

Funder types: Other

Identifiers

NCT07130331

2025-0544-02

Details and patient eligibility

About

This study aimed to explore the efficacy and influencing factors of secukinumab in axSpA patients by conducting a real-world retrospective analysis.

Full description

Interleukin-17 (IL-17) plays a key role in axSpA joint inflammation, cartilage injury and bone remodeling.The 2022 ASAS-EULAR recommendations recommended the use of IL-17 inhibitors as first-line therapy for patients who have had an inadequate response to conventional agents including non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Secukinumab, a fully human monoclonal IgG1/κ antibody targeting IL-17A, was approved in the US in 2016 for the treatment of AS and in 2020 for the treatment of nr-axSpA. Although several studies have shown that secukinumab significantly reduces pain symptoms and diseases activity in axSpA patients, a significant proportion of patients experience treatment failure during the maintenance phase. This study aimed to explore the efficacy and influencing factors of secukinumab in axSpA patients by conducting a retrospective analysis in a real-world setting.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Meet the 2011 Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis
2. Treated with secukinumab with regular follow up
3. Patients who visited the Rheumatology clinic from Jun 2020 to Jul 2024 retrieved by Hospital Information System

Exclusion criteria

1. allergic to secukinumab
2. concomitant with other rheumatic immune diseases
3. patients with malignancies or serious infections
4. patients with poor compliance and lost to follow-up

Trial design

200 participants in 1 patient group

Patients with axial spondyloarthritis

Description:

Patients with axial spondyloarthritis

Treatment:

Drug: Secikinumab